Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.40 |
| ▸ | HTR1A | P08908 | 6/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2086005 | 0.84 | SSTR4 (0.40) | SLC6A4SLC6A2HTR1ASSTR4CHRM2 | |
| SCHEMBL7140521 | 0.73 | NOS3 (0.47) | SSTR4CXCR4NOS3NOS1NOS2 | |
| SCHEMBL19214826 | 0.72 | NOS3 (0.45) | SLC6A4SLC6A2SSTR4CXCR4SLC6A3 | |
| SCHEMBL2083529 | 0.71 | SLC6A2 (0.50) | SLC6A4SLC6A2HTR1ACHRM2CHRM4 | |
| SCHEMBL2083712 | 0.70 | NOS3 (0.40) | SSTR4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2080658 | 0.69 | CXCR4 (0.43) | SLC6A4SLC6A2HTR1ASSTR4HTR2C | |
| SCHEMBL3304652 | 0.69 | SLC6A4 (0.42) | SLC6A4SLC6A2HTR1ASSTR4HTR2C | |
| SCHEMBL20031862 | 0.69 | NOS3 (0.42) | SSTR4CXCR4NOS3NOS1NOS2 | |
| SCHEMBL19214821 | 0.68 | NOS3 (0.41) | SSTR4CXCR4NOS3NOS1NOS2 | |
| SCHEMBL10190919 | 0.68 | NOS3 (0.43) | SSTR4CHRM4CXCR4NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1613613-A4 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2009-03-25 | — | — | EP | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1613613-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | SLC6A4 2898/4885SLC6A2 2690/4885HTR1A 557/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | SLC6A4 2328/4885SLC6A2 2411/4885HTR1A 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.